ArticleCancers2025

Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study.

Lina Zoe Rüsing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.